CLAIMS

1. Use of a caspase-3 inhibitor in the manufacture of a medicament for treating a wound in a subject, wherein a therapeutically effective amount of the caspase-3 inhibitor is to be administered to the subject.

2. The use of claim 1, wherein the wound is a chronic wound; optionally wherein the wound is an epithelial wound; further optionally wherein the wound is a cutaneous wound.

3. The use of claim 1 or 2, wherein the caspase-3 inhibitor is a small molecule, peptide, polypeptide, nucleic acid, or a combination thereof.

4. The use of claim 3, wherein the caspase-3 inhibitor is flubendazole, fenoprofen, diflunisal, pranoprofen, or a pharmaceutically acceptable salt or solvate thereof.

5. The use of any one of claims 1 to 4, wherein the caspase-3 inhibitor is administered at or near the wound site.

6. The use of any one of claims 1 to 5, wherein the subject has compromised wound healing ability; optionally wherein the subject is a mammal.

7. The use of any one of claims 1 to 6, wherein the caspase-3 inhibitor promotes re-epithelialisation of the wound.

8. The use of any one of claims 1 to 7, wherein the caspase-3 inhibitor is administered simultaneously or sequentially with a therapeutically effective amount of spermine and/or spermidine.

9. Use of a caspase-3 inhibitor in the manufacture of a medicament for promoting re-epithelialisation of a wound in a subject, wherein a therapeutically effective amount of the caspase-3 inhibitor is to be administered to the subject.

10. A method of detecting a chronic wound in a subject, the method comprising detecting the level of cleaved caspase-3 and/or caspase-3 activity in a sample from the subject, wherein an increase in the level of cleaved caspase-3 and/or caspase-3 activity, relative to a reference, indicates that the subject has a chronic wound; optionally wherein the sample is a wound sample.

11. The method of claim 10, wherein the level of cleaved caspase-3 and/or caspase-3 activity is detected over a period of time, and wherein a sustained increase in the level of cleaved caspase-3 and/or caspase-3 activity over the period of time, relative to a reference, indicates that the subject has a chronic wound; optionally wherein the time period is at least 5 days.

12. A pharmaceutical composition comprising (a) a caspase-3 inhibitor and (b) spermine and/or spermidine; optionally wherein the pharmaceutical composition is a topical composition.

13. A pharmaceutical combination comprising (a) a caspase-3 inhibitor and (b) spermine and/or spermidine.

14. A pharmaceutical composition of claim 12, or a pharmaceutical combination of claim 13, for use as a medicament.

15. Use of a pharmaceutical composition of claim 12, or a pharmaceutical combination of claim 13, in the manufacture of a medicament for treating a wound in a subject.